Faculty Opinions recommendation of Intestinal glucose absorption was reduced by vertical sleeve gastrectomy via decreased gastric leptin secretion.

Author(s):  
Richard J Naftalin
2018 ◽  
Vol 28 (12) ◽  
pp. 3851-3861 ◽  
Author(s):  
Jinpeng Du ◽  
Chaojie Hu ◽  
Jie Bai ◽  
Miaomiao Peng ◽  
Qingbo Wang ◽  
...  

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2474
Author(s):  
Lyudmila V. Gromova ◽  
Serguei O. Fetissov ◽  
Andrey A. Gruzdkov

The worldwide prevalence of metabolic diseases such as obesity, metabolic syndrome and type 2 diabetes shows an upward trend in recent decades. A characteristic feature of these diseases is hyperglycemia which can be associated with hyperphagia. Absorption of glucose in the small intestine physiologically contributes to the regulation of blood glucose levels, and hence, appears as a putative target for treatment of hyperglycemia. In fact, recent progress in understanding the molecular and cellular mechanisms of glucose absorption in the gut and its reabsorption in the kidney helped to develop a new strategy of diabetes treatment. Changes in blood glucose levels are also involved in regulation of appetite, suggesting that glucose absorption may be relevant to hyperphagia in metabolic diseases. In this review we discuss the mechanisms of glucose absorption in the small intestine in physiological conditions and their alterations in metabolic diseases as well as their relevance to the regulation of appetite. The key role of SGLT1 transporter in intestinal glucose absorption in both physiological conditions and in diabetes was clearly established. We conclude that although inhibition of small intestinal glucose absorption represents a valuable target for the treatment of hyperglycemia, it is not always suitable for the treatment of hyperphagia. In fact, independent regulation of glucose absorption and appetite requires a more complex approach for the treatment of metabolic diseases.


Surgery ◽  
2016 ◽  
Vol 160 (6) ◽  
pp. 1496-1507 ◽  
Author(s):  
Yehui Du ◽  
Hao Chen ◽  
Zefeng Xuan ◽  
Wenfeng Song ◽  
Liangjie Hong ◽  
...  

2016 ◽  
Vol 12 (7) ◽  
pp. S212-S213
Author(s):  
Jacqueline Paolino ◽  
Sajani Shah ◽  
Wesley Vosburg ◽  
Julie Kim ◽  
Adam Blau ◽  
...  

2018 ◽  
Vol 132 (2) ◽  
pp. 295-312 ◽  
Author(s):  
Redin A. Spann ◽  
William J. Lawson ◽  
Gene L. Bidwell ◽  
C. Austin Zamarripa ◽  
Rodrigo O. Maranon ◽  
...  

Bariatric surgery is increasingly employed to improve fertility and reduce obesity-related co-morbidities in obese women. Surgical weight loss not only improves the chance of conception but reduces the risk of pregnancy complications including pre-eclampsia, gestational diabetes, and macrosomia. However, bariatric procedures increase the incidence of intrauterine growth restriction (IUGR), fetal demise, thromboembolism, and other gestational disorders. Using our rodent model of vertical sleeve gastrectomy (VSG), we tested the hypothesis that VSG in diet-induced, obese dams would cause immune and placental structural abnormalities that may be responsible for fetal demise during pregnancy. VSG dams studied on gestational day (G) 19 had reduced circulating T-cell (CD3+ and CD8+) populations compared with lean or obese controls. Further, local interleukin (IL) 1β and IL 1 receptor antagonist (il1rn) cmRNA were increased in placenta of VSG dams. Placental barrier function was also affected, with increased transplacental permeability to small molecules, increased matrix metalloproteinase 9 expression, and increased apoptosis in VSG. Furthermore, we identified increased placental mTOR signaling that may contribute to preserving the body weight of the fetuses during gestation. These changes occurred in the absence of a macronutrient deficit or gestational hypertension in the VSG dams. In summary, previous VSG in dams may contribute to fetal demise by affecting maternal immune system activity and compromise placental integrity.


Sign in / Sign up

Export Citation Format

Share Document